The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.
 
Wolfgang Wick
Consulting or Advisory Role - MSD Oncology (Inst); Roche/Genentech (Inst)
Research Funding - Apogenix (Inst); Pfizer (Inst); Roche (Inst)
 
Ahmed Idbaih
Honoraria - Leo Pharma; Novocure
Consulting or Advisory Role - Health Advances
Research Funding - Air Liquide (Inst); CarThera (Inst); Nutritheragene (Inst); Sanofi (Inst); SERVIER (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - CarThera; Leo Pharma; Novocure
 
Ghazaleh Tabatabai
Honoraria - Abbvie; Bayer
Consulting or Advisory Role - Abbvie; Bayer; Boehringer Ingelheim
 
María Vieito
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Roche
 
Agostina Stradella
No Relationships to Disclose
 
François Ghiringhelli
Honoraria - roche
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech
 
Michael C. Burger
No Relationships to Disclose
 
Iris Mildenberger
No Relationships to Disclose
 
Ulrich Herrlinger
Stock and Other Ownership Interests - BioNTech; ETF
Consulting or Advisory Role - Bayer
Speakers' Bureau - Medac
 
Mirjam Renovanz
Research Funding - German Innovation Fund
 
Mehdi Touat
Consulting or Advisory Role - Agios; IntegraGen; SERVIER; Taiho Pharmaceutical
Research Funding - Sanofi
Travel, Accommodations, Expenses - Merck Sharp & Dohme; SERVIER
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Black Diamond Therapeutics; Blue Earth Diagnostics; Boston Pharmaceuticals; Celularity; Chimerix; Day One Biopharmaceuticals; ElevateBio; Imvax; Integral Health; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Novocure; Nuvation Bio; Prelude Therapeutics; QED Therapeutics; Sapience Therapeutics; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Research Funding - Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Chimerix (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Antje Wick
No Relationships to Disclose
 
Christophe Bonny
Employment - Enterome
Leadership - Enterome
Stock and Other Ownership Interests - Enterome
Travel, Accommodations, Expenses - Enterome
 
Jan Fagerberg
Employment - Enterome
Leadership - Enterome
Stock and Other Ownership Interests - Enterome
Travel, Accommodations, Expenses - Enterome
 
Cécile Gouttefangeas
Research Funding - Enterome; RhoVac
Patents, Royalties, Other Intellectual Property - IMMUNOLOGY DEPARTMENT TUEBINGEN; RhoVac
 
Ana Maia
Research Funding - Enterome
 
David A. Reardon
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novocure; Oncorus; Regeneron; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Omniox